Drug eruption: A mimicker of Coronavirus disease-2019 rash

Q4 Medicine
T. Ergun, I. Ergenc, Seda Seven, D. Seckin, Elif Cömert Özer, Meryem Aktas, Elif Tükenmez Tigen
{"title":"Drug eruption: A mimicker of Coronavirus disease-2019 rash","authors":"T. Ergun, I. Ergenc, Seda Seven, D. Seckin, Elif Cömert Özer, Meryem Aktas, Elif Tükenmez Tigen","doi":"10.4274/turkderm.galenos.2021.29904","DOIUrl":null,"url":null,"abstract":"Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkderm-Archives of the Turkish Dermatology and Venerology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/turkderm.galenos.2021.29904","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.
药疹:模仿冠状病毒病-2019皮疹
严重急性呼吸综合征-冠状病毒-2 (SARS-CoV-2)感染可伴有几种皮肤病变,其中黄斑丘疹最为常见。用于治疗冠状病毒病-2019 (COVID-19)的药物也可能引起斑疹。区分病毒性皮疹和药疹可能很困难,特别是在COVID-19使用几种药物的情况下。因此,本研究旨在描述6例COVID-19患者的皮肤表现,并强调区分sars - cov -2相关皮疹和药疹的特征。2020年3月至6月期间,有1492名患者因COVID-19住院并在马尔马拉大学医院接受羟氯喹治疗。其中6例因可能与新冠肺炎相关的皮疹或药物反应而就诊。羟氯喹单药治疗1例。6例患者均在出现COVID-19症状后5-21天出现红斑、对称和黄斑丘疹,主要累及躯干、腋窝和生殖农村区域。5例患者在治疗结束后4-11天出现皮疹。瘙痒很严重。所有患者均接受局部皮质类固醇和口服抗组胺药治疗,这提供了部分缓解。火山喷发的消退通常很慢,需要几周时间。新冠病毒症状和爆发之间的时间较长,恢复缓慢,有利于药物爆发。共存病毒感染是众所周知的促药疹因子,其对新冠肺炎患者药物不良反应的促进作用有待进一步观察和研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
52
审稿时长
6-12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信